1. Andreeva, L.A., Mezentseva, M.V., Narovlyanskii, A.N., et al., The perspectives of development of new peptide preparations for clinical use which have anti-infection and immune-modulating activity, Infektsiya i Immunitet, 2011, vol. 1, no. 2, pp. 171–176.
2. Arushanyan, E.B. and Borovkova, G.K., Lekarstvennye sredstva, vliyayushchie na funktsiyu efferentnykh nervov: uchebnoe posobie (Drugs Affecting the Function of Efferent Nerves: A Study Guide), Stavropol: Stavropol. Gos. Med. Univ., 2016.
3. Ashmarin, I.P. Structure-function classification of regulatory peptides: What should be included for minimum understanding by a wide variety of neurochemists, neurophysiologists, and senior and post-graduate students, Neurochem. J., 2007, vol. 1, no. 4, pp. 334–338.
4. Bennett, J.A., Ture, S.K., Schmidt, R.A., et al., Acetylcholine inhibits platelet activation, J. Pharmacol. Exp. Ther., 2019, vol. 369, no. 2, pp. 182–187.
5. Cavun, S., Savci, V., and Ulus, I.H., Centrally injected CDP–choline increases plasma vasopressin levels by central cholinergic activation, Fundam. Clin. Pharmacol., 2004, vol. 18, no. 1, pp. 71–77.